Since 1993, the AACR has awarded more than $542 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
Dr. Sonia del Rincón and the Stand Up to Cancer (SU2C) Canada Metastatic Breast Cancer Dream Team are looking to understand the impact of MAP kinase–interacting serine/threonine kinases 1 and 2 (MNK1/2) inhibitors on metastatic breast cancer...
Pancreatic cancer is forecasted to become the 2nd deadliest cancer in the United States by 2030. The AACR, in partnership with the Lustgarten Foundation and Pancreatic Cancer Action Network (PanCAN), brought together top scientists in the AACR Special Conference...
AACR grantee Sergey Karakashev, PhD, and colleagues at the Wistar Institute have recently shown that the efficacy of PARP inhibitors can be extended to HR-proficient epithelial ovarian cancers using a combinatorial approach with inhibitors of the histone-modifying enzyme EZH2.